Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Total Liabilities : ¥932.9 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Wuhan Easy Diagnosis Biomedicine Co Total Liabilities?

Wuhan Easy Diagnosis Biomedicine Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥932.9 Mil.

Wuhan Easy Diagnosis Biomedicine Co's quarterly Total Liabilities declined from Sep. 2023 (¥1,319.13 Mil) to Dec. 2023 (¥1,094.50 Mil) and declined from Dec. 2023 (¥1,094.50 Mil) to Mar. 2024 (¥932.94 Mil).

Wuhan Easy Diagnosis Biomedicine Co's annual Total Liabilities increased from Dec. 2021 (¥567.02 Mil) to Dec. 2022 (¥2,422.72 Mil) but then declined from Dec. 2022 (¥2,422.72 Mil) to Dec. 2023 (¥1,094.50 Mil).

Wuhan Easy Diagnosis Biomedicine Co Total Liabilities Historical Data

The historical data trend for Wuhan Easy Diagnosis Biomedicine Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Easy Diagnosis Biomedicine Co Total Liabilities Chart

Wuhan Easy Diagnosis Biomedicine Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

22.80

318.47

567.02

2,422.72

1,094.50

Wuhan Easy Diagnosis Biomedicine Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2,004.59	1,628.43	1,319.13	1,094.50	932.94

Wuhan Easy Diagnosis Biomedicine Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Wuhan Easy Diagnosis Biomedicine Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1019.362	+	(18.253	+	56.883
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,094.5

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	7386.6	-	6292.101
	=	1,094.5

Wuhan Easy Diagnosis Biomedicine Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	858.191	+	(17.807	+	56.94
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	932.9

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	7240.838	-	6307.9
	=	932.9

Wuhan Easy Diagnosis Biomedicine Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Wuhan Easy Diagnosis Biomedicine Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wuhan Easy Diagnosis Biomedicine Co Ltd (SZSE:002932) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Dongxin Road, 2 Floor, Building E, International Students Pioneer Park, Guandong Science and Technology Park, Donghu Development Zone, Hubei, Wuhan, CHN, 430075

Website

http://www.mdeasydiagnosis.com

Wuhan Easy Diagnosis Biomedicine Co Ltd is engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments and mobile ECG products. The company's product profile consists of Molecular diagnosis, Chemiluminescence, Blood gas analysis, and others. It also provides various other solutions such as Mingde Biomolecular Diagnostic Service Solution, Mingde Biothoracic Center Solution, POCT Solution, Remote ECG network construction solution, and others.

Executives

Wang Rui	Directors, executives
Wang Jian Fei	Director

Wuhan Easy Diagnosis Biomedicine Co (SZSE:002932) Headlines

No Headlines